This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gonzalez-Gronow, M. Articles by Pizzo, S. V. Search for Related Content PubMed PubMed Citation Articles by Gonzalez-Gronow, M. Articles by Pizzo, S. V.

Prostate Cancer Cell Proliferation In vitro Is Modulated by Antibodies against Glucose-Regulated Protein 78 Isolated from Patient Serum

¹ Department of Pathology, Duke University Medical Center, Durham, North Carolina; ² Department of Medicine, Clinical Hospital of the University of Chile; and ³ Department of Urology, El Salvador Hospital, Santiago, Chile

Requests for reprints: Mario Gonzalez-Gronow, Department of Pathology, Duke University Medical Center, Box 3712, Durham, NC 27710. Phone: 919-684-8879; Fax: 919-684-8689; E-mail: gonza002{at}mc.duke.edu.

Circulating autoantibodies against the glucose-regulated protein of 78 kDa (GRP78) are present at high levels in prostate cancer patients and are a biomarker of aggressive tumor behavior. We purified the anti-GRP78 IgGs and examined their effect on 1-LN, PC-3, DU145, and LnCap human prostate cancer cells. We also evaluated its effects on the breast cancer MDA-MB231 and melanoma DM413 cell lines. The anti-GRP78 antibody binds only to cells expressing GRP78 on the surface, to a site also recognized by its physiologic agonist, activated ₂-macroglobulin (₂M*). This antibody is completely specific for a peptide, including the primary amino acid sequence CNVKSDKSC, which contains a tertiary structural motif mimicking an epitope in GRP78. Tertiary structual analysis suggested the linear GRP78 primary amino acid sequence LIGRTWNDPSVQQDIKFL (Leu⁹⁸-Leu¹¹⁵) as the putative binding site, containing the tertiary structual arrangement described above, which was confirmed experimentally. The anti-GRP78 antibodies from prostate cancer patients recognize almost exclusively this epitope. We produced animal antibodies against both these peptides, and they are able to mimic the effects of the human antibody. Our experiments also suggest this epitope as highly immunogenic, thereby explaining the specificity of the immune response against this epitope in GRP78, observed in humans. Using 1-LN cells as a model, we show that anti-GRP78 IgG purified from the sera of these patients mimics the proproliferative effects induced by ₂M* via the common receptor, GRP78. Furthermore, increasing concentrations of human anti-GRP78 IgG show a dose-dependent protective effect on apoptosis induced by tumor necrosis factor . (Cancer Res 2006; 66(23): 11424-31)

This article has been cited by other articles:

				U. K. Misra, Y. Mowery, S. Kaczowka, and S. V. Pizzo Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis Mol. Cancer Ther., May 1, 2009; 8(5): 1350 - 1362. [Abstract] [Full Text] [PDF]

				M. Gonzalez-Gronow, S. J. Kaczowka, S. Payne, F. Wang, G. Gawdi, and S. V. Pizzo Plasminogen Structural Domains Exhibit Different Functions When Associated with Cell Surface GRP78 or the Voltage-dependent Anion Channel J. Biol. Chem., November 9, 2007; 282(45): 32811 - 32820. [Abstract] [Full Text] [PDF]

				C. G. Jakobsen, N. Rasmussen, A.-V. Laenkholm, and H. J. Ditzel Phage Display Derived Human Monoclonal Antibodies Isolated by Binding to the Surface of Live Primary Breast Cancer Cells Recognize GRP78 Cancer Res., October 1, 2007; 67(19): 9507 - 9517. [Abstract] [Full Text] [PDF]

				A. S. Lee GRP78 Induction in Cancer: Therapeutic and Prognostic Implications Cancer Res., April 15, 2007; 67(8): 3496 - 3499. [Abstract] [Full Text] [PDF]